One physician is slacking off while the rest of you see more patients, take after-hours calls and pitch in when necessary. Find out the best ways to deal with this situation. Medscape Business of Medicine
Category: News
Promedior Announces Presentation Of Preclinical Data At ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization In Retinal Diseases
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) were presented …
Promedior Announces Presentation Of Preclinical Data At ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization In Retinal Diseases
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, announced that data from preclinical studies of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) were presented …
Phase 2 Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients Presented At ARVO 2011
Sucampo Pharmaceuticals, Inc. (“Sucampo”), (NASDAQ: SCMP) today reported data from a proof of concept phase 2 clinical trial conducted by R-Tech Ueno, Ltd. (“RTU”, JASDAQ: 4573), of UF-021 (unoprostone isopropyl) in 112 patients with retinitis pigmento…
Phase 2 Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients Presented At ARVO 2011
Sucampo Pharmaceuticals, Inc. (“Sucampo”), (NASDAQ: SCMP) today reported data from a proof of concept phase 2 clinical trial conducted by R-Tech Ueno, Ltd. (“RTU”, JASDAQ: 4573), of UF-021 (unoprostone isopropyl) in 112 patients with retinitis pigmento…
Study demonstrates value of MicroPulse technology for diabetic macular edema treatment
IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the …
Research experts to speak at brain tumor educational conference
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
Study Demonstrates Benefits Of MicroPulse™ Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation (Nasdaq: IRIX) announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers,…
Study Demonstrates Benefits Of MicroPulse™ Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation (Nasdaq: IRIX) announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers,…
MiMedx introduces AmnioFix Nerve Wrap for use in surgical procedures
MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company’s latest biolog…
The Myths Surrounding Latisse: Will It Turn My Blue Eyes Brown?
Featured Article
Dizzy After Cataract Surgery: An Interactive Case
Featured Article
3-D in Ophthalmology
Technology Spotlight
Corticosteroid Implant More Effective In Patients With Longer Duration Of DME
Two phase 3 clinical trials showed that patients who received fluocinolone acetonide implants for diabetic macular edema achieved better visual results if they had longer disease duration before treatment, according to a speaker here.
ARVO: Once-Daily Glaucoma Drug Shows Promise
(MedPage Today) — An investigational, once-daily drug called tafluprost appears to lower intraocular pressure at least as well as a twice-daily glaucoma drug, researchers found.
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
Study Demonstrates Benefits Of MicroPulse Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…